HOUSE 2115116th CongressReceived in the Senate and Read twice and referred to the Committee on Finance.

Public Disclosure of Drug Discounts and Real-Time Beneficiary Drug Cost Act

Last Action: 10/29/2019

Actions

2019-10-29Received in the Senate and Read twice and referred to the Committee on Finance.
2019-10-28The title of the measure was amended. Agreed to without objection.
2019-10-28Motion to reconsider laid on the table Agreed to without objection.
2019-10-28On motion to suspend the rules and pass the bill, as amended Agreed to by the Yeas and Nays: (2/3 required): 403 - 0 (Roll no. 586). (text: CR H8516)
2019-10-28Passed/agreed to in House: On motion to suspend the rules and pass the bill, as amended Agreed to by the Yeas and Nays: (2/3 required): 403 - 0 (Roll no. 586).(text: CR H8516)
2019-10-28Considered as unfinished business. (consideration: CR H8520-8521)
2019-10-28At the conclusion of debate, the Yeas and Nays were demanded and ordered. Pursuant to the provisions of clause 8, rule XX, the Chair announced that further proceedings on the motion would be postponed.
2019-10-28DEBATE - The House proceeded with forty minutes of debate on H.R. 2115.
2019-10-28Considered under suspension of the rules. (consideration: CR H8516-8519)
2019-10-28Ms. Schakowsky moved to suspend the rules and pass the bill, as amended.
2019-05-21Subcommittee Hearings Held.
2019-04-09Referred to the Subcommittee on Health.
2019-04-08Referred to the Subcommittee on Health.
2019-04-08Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
2019-04-08Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.

Showing 15 of 17 actions. Full history on Congress.gov.

CRS Summary

As of 2019-10-28 (53)

Public Disclosure of Drug Discounts and Real-Time Beneficiary Drug Cost Act

This bill requires the Centers for Medicare & Medicaid Services (CMS) to publish certain payment information regarding pharmacy benefit managers (PBMs) and prescription drugs. Specifically, the CMS must publish certain information, as reported by PBMs, relating to generic dispensing rates, drug discounts and rebates, and payments between PBMs, health plans, and pharmacies, in accordance with specified confidentiality requirements.

The bill also provides statutory authority for certain provisions of the CMS rule titled "Modernizing Part D and Medicare Advantage to Lower Drug Prices and Reduce Out-of-Pocket Expenses," published on May 23, 2019. The rule requires, in part, Medicare prescription drug plan sponsors to implement an electronic, real-time benefit tool that is capable of integrating with at least one prescriber's electronic prescribing system or electronic health record. The tool must provide prescribers with patient-specific, real-time formulary and benefit information, including information regarding cost-sharing, formulary alternatives, and utilization management requirements. The rule takes effect January 1, 2021.

Cosponsors (5)

Jodey Arrington (R-TX)
Brendan Boyle (D-PA)
Jefferson Van Drew (D-NJ)
Elissa Slotkin (D-MI)
Van Taylor (R-TX)

Subjects

Business records
Government information and archives
Health care costs and insurance
Inflation and prices
Prescription drugs
Retail and wholesale trades

Read on Congress.gov

Sourced from Congress.gov (public domain).

This is legal information, not legal advice. Laws vary by jurisdiction and change frequently. Always verify current law with official sources and consult a licensed attorney in your jurisdiction for advice on your specific situation.